These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33316313)

  • 1. Order of discontinuation of glucose-lowering medications following bariatric surgery.
    Vouri SM; Chen J; Sparkman J; Salles A; Micek ST
    Diabetes Res Clin Pract; 2021 Feb; 172():108580. PubMed ID: 33316313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study.
    Fadini GP; Li Volsi P; Devangelio E; Poli M; Cazzetta G; Felace G; Avogaro A;
    J Endocrinol Invest; 2020 Mar; 43(3):329-336. PubMed ID: 31515744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study.
    Bloomgarden ZT; Tunceli K; Liu J; Brodovicz KG; Mavros P; Engel SS; Radican L; Chen Y; Rajpathak S; Qiu Y; Brudi P; Fonseca V
    J Diabetes; 2017 Jul; 9(7):677-688. PubMed ID: 27531167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of diabetes medication in the 10 years before death in Denmark: a register-based study.
    Kosjerina V; Carstensen B; Jørgensen ME; Brock B; Christensen HR; Rungby J; Andersen GS
    Lancet Healthy Longev; 2021 Sep; 2(9):e561-e570. PubMed ID: 36098008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
    Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
    JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
    Verburg AFE; van den Donk M; Wiersma T
    Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.
    Bachmann KN; Roumie CL; Wiese AD; Grijalva CG; Buse JB; Bradford R; Zalimeni EO; Knoepp P; Dard S; Morris HL; Donahoo WT; Fanous N; Fonseca V; Katalenich B; Choi S; Louzao D; O'Brien E; Cook MM; Rothman RL; Chakkalakal RJ
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00637. PubMed ID: 32881317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative adherence to diabetes drugs: An analysis of electronic health records and claims data.
    Flory J; Gerhard T; Stempniewicz N; Keating S; Rowan CG
    Diabetes Obes Metab; 2017 Aug; 19(8):1184-1187. PubMed ID: 28266807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Diabetes in Patients Undergoing Bariatric Surgery.
    Mulla CM; Baloch HM; Hafida S
    Curr Diab Rep; 2019 Nov; 19(11):112. PubMed ID: 31686263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.
    Takahashi M; Shibasaki M; Echizen H; Kushiyama A
    PLoS One; 2020; 15(7):e0236603. PubMed ID: 32706828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to modification of antidiabetic therapy in patients over the age of 65 years with newly diagnosed diabetes mellitus.
    Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A
    Diabetes Res Clin Pract; 2020 Apr; 162():108090. PubMed ID: 32088311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
    Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
    Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
    Lozano-Ortega G; Goring S; Bennett HA; Bergenheim K; Sternhufvud C; Mukherjee J
    Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
    Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.
    Desai NR; Shrank WH; Fischer MA; Avorn J; Liberman JN; Schneeweiss S; Pakes J; Brennan TA; Choudhry NK
    Am J Med; 2012 Mar; 125(3):302.e1-7. PubMed ID: 22340932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of DPP-4 inhibitors and SGLT2 inhibitors compared to sulphonylureas in adult patients with diabetes with low c-peptide levels with or without anti-GAD65 antibody positivity.
    Sudan A; Kalra A; Mirza AA; Kant R
    Diabetes Metab Syndr; 2021; 15(4):102197. PubMed ID: 34245964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.